Navigation Links
Review Urges Aggressive MRSA Screening for Health Workers
Date:4/21/2008

Even good adherence to infection control did not entirely prevent transmission, study finds

MONDAY, April 21 (HealthDay News) -- In hospitals and other health-care facilities with endemic methicillin-resistant Staphylococcus aureus (MRSA), aggressive screening of health-care workers should be combined with other measures to help reduce infection rates, new research suggests.

The Swiss and South African authors, who reviewed data from 169 studies of 33,318 health-care workers in 37 countries, found that 4.6 percent of the workers carried MRSA, and, of these, 5.1 percent had clinical MRSA infections.

"Poor infection control practices were implicated in both acquisition and transmission of MRSA by personnel, but even good adherence to infection control -- including masks and hand hygiene -- did not entirely prevent transmission of MRSA from heavily colonized staff to patients," they wrote.

A recent review of MRSA outbreaks suggested that health-care worker screening should focus on those with symptoms of MRSA infection, but this approach would likely miss a large number of MRSA-infected workers with no symptoms, the review authors said.

"Screening of infected health-care workers only will likely miss a large number of asymptomatic personnel capable of transmitting MRSA to patients, since staphylococcal carriage is mainly dependent on whether the person is a nasal carrier (of MRSA)... Our search revealed 18 studies with proven, and 26 studies with likely, transmission to patients from (health-care workers) who were not clinically infected with MRSA," the authors wrote.

Screening of health-care workers should be conducted "irrespective of the presence of risk factors or pus-producing infections as part of pre-employment examination, or [especially during large MRSA outbreaks] even periodically and unannounced before a work shift," they said.

In addition, nose and throat samples should be taken with separate swabs, since MRSA eradication therapy differs depending on the location of the MRSA, the authors recommended.

They acknowledged that cost makes MRSA screening unfeasible in many health-care facilities but noted that close health-care worker surveillance is conducted in regions -- such as Scandinavia, the Netherlands and Western Australia -- with low MRSA prevalence.

"We recommend screening of health care workers during outbreak investigations and during early stages of an institutional epidemic when MRSA prevalence is still low or when a new MRSA strain is propagating rapidly. In settings with endemic MRSA or limited resources, priority should be given to staff in high risk units such as intensive care units, burn units, or surgical wards," the review authors wrote.

The review was expected to be published in the May issue of the The Lancet Infectious Diseases.

More information

The U.S. Centers for Disease Control and Prevention has more about MRSA in health-care settings.



-- Robert Preidt



SOURCE: The Lancet, news release, April 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology: